We have located links that may give you full text access.
Recognition and Epileptology of Protracted CLN3 Disease.
Epilepsia 2023 April 12
OBJECTIVE: To analyse phenotypic features of a cohort of patients with protracted CLN3 disease to improve recognition of the disorder.
METHODS: We analysed phenotypic data of ten patients from six families with protracted CLN3 disease. Haplotype analysis was performed in three reportedly unrelated families.
RESULTS: Visual impairment was the initial symptom with onset at 5-9 years, similar to classic CLN3 disease. Mean time from onset of visual impairment to seizures was 12 years (range 6-41 years). Various seizure types were reported, most commonly generalized tonic-clonic seizures (GTCS); focal seizures were present in four patients. Progressive myoclonus epilepsy was not seen. Inter-ictal EEG revealed mild background slowing and 2.5-3.5Hz spontaneous generalized spike-wave discharges. Additional inter-ictal focal epileptiform discharges were noted in some patients. Age at death for the three deceased patients was 31, 31 and 52 years. Molecular testing revealed five individuals were homozygous for c.461-280_677+382del966, the 'common 1 kilobase pair' CLN3 deletion. The remaining individuals were compound heterozygous for various combinations of recurrent pathogenic CLN3 variants. Haplotype analysis demonstrated evidence of a common founder for the common 1 kb deletion. Dating analysis suggested the deletion arose approximately 1,500 years ago. and thus did not represent cryptic familial relationship in this Australian cohort.
SIGNIFICANCE: We highlight the protracted phenotype of a disease generally associated with death in adolescence, which is a combined focal and generalized epilepsy syndrome with progressive neurological deterioration. The disorder should be suspected in an adolescent or adult patient presenting with generalized or focal seizures preceded by progressive visual loss. The common 1kB deletion has been typically associated with classic CLN3 disease, and the protracted phenotype has not previously been reported with this genotype. This suggests that modifying genetic factors may be important in determining this somewhat milder phenotype and identification of these factors should be the subject of future research.
METHODS: We analysed phenotypic data of ten patients from six families with protracted CLN3 disease. Haplotype analysis was performed in three reportedly unrelated families.
RESULTS: Visual impairment was the initial symptom with onset at 5-9 years, similar to classic CLN3 disease. Mean time from onset of visual impairment to seizures was 12 years (range 6-41 years). Various seizure types were reported, most commonly generalized tonic-clonic seizures (GTCS); focal seizures were present in four patients. Progressive myoclonus epilepsy was not seen. Inter-ictal EEG revealed mild background slowing and 2.5-3.5Hz spontaneous generalized spike-wave discharges. Additional inter-ictal focal epileptiform discharges were noted in some patients. Age at death for the three deceased patients was 31, 31 and 52 years. Molecular testing revealed five individuals were homozygous for c.461-280_677+382del966, the 'common 1 kilobase pair' CLN3 deletion. The remaining individuals were compound heterozygous for various combinations of recurrent pathogenic CLN3 variants. Haplotype analysis demonstrated evidence of a common founder for the common 1 kb deletion. Dating analysis suggested the deletion arose approximately 1,500 years ago. and thus did not represent cryptic familial relationship in this Australian cohort.
SIGNIFICANCE: We highlight the protracted phenotype of a disease generally associated with death in adolescence, which is a combined focal and generalized epilepsy syndrome with progressive neurological deterioration. The disorder should be suspected in an adolescent or adult patient presenting with generalized or focal seizures preceded by progressive visual loss. The common 1kB deletion has been typically associated with classic CLN3 disease, and the protracted phenotype has not previously been reported with this genotype. This suggests that modifying genetic factors may be important in determining this somewhat milder phenotype and identification of these factors should be the subject of future research.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app